Tan, Yong Zi http://orcid.org/0000-0001-6656-6320
Aiyer, Sriram http://orcid.org/0000-0001-6436-0521
Mietzsch, Mario
Hull, Joshua A.
McKenna, Robert
Grieger, Joshua
Samulski, R. Jude
Baker, Timothy S.
Agbandje-McKenna, Mavis
Lyumkis, Dmitry http://orcid.org/0000-0002-8124-7472
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (1R01AI136680)
U.S. Department of Health & Human Services | NIH | NIH Office of the Director (5DP5OD021396)
Article History
Received: 10 July 2018
Accepted: 11 August 2018
First Online: 7 September 2018
Competing interests
: M.A.M. is a SAB member for Voyager Therapeutics, Inc., and AGTC, has a sponsored research agreement with AGTC and Voyager Therapeutics, and is a consultant for Intima Biosciences, Inc. M.A.M. is a co-founder of StrideBio, Inc. This is a biopharmaceutical company with interest in developing AAV vectors for gene delivery application. R.J.S. is the scientific founder of Bamboo Therapeutics, Asklepios Biopharmaceutics, Chatham Therapeutics, and Merlin. These companies also have interest in the development of AAV for gene delivery applications. The remaining authors declare no competing interests.